Table 1.
Clinical Trials Targeting Fibroblasts in PDAC.
| Strategy | Therapeutic | Trial Phase | Trial Status | NCT Number |
|---|---|---|---|---|
| Disrupt CAF Signaling | Tocilizumab | 1b/2 | Recruiting | NCT03193190 |
| Tocilizumab | 2 | Recruiting | NCT02767557 | |
| Tocilizumab | 2 | Active | NCT04258150 | |
| Siltuximab | 1,2 | Recruiting | NCT04191421 | |
| Canakinumab | 1 | Recruiting | NCT04581343 | |
| Plerixafor | 2 | Recruiting | NCT04177810 | |
| Plerixafor | 1 | Completed | NCT02179970 | |
| BL-8040 | 2 | Active | NCT02826486 | |
| Reprogramming to Quiescence | ATRA 1 | 1 | Completed | NCT03307148 |
| ATRA 1 | 2 | Not yet recruiting | NCT04241276 | |
| Vitamin D3 | 3 | Recruiting | NCT03472833 | |
| Paricalcitrol | 2 | Completed | NCT03331562 | |
| Paricalcitrol | 1 | Recruiting | NCT03519308 | |
| Paricalcitrol | 2 | Recruiting | NCT04617067 | |
| Paricalcitrol | 1 | Active | NCT03883919 | |
| Paricalcitrol | 2 | Recruiting | NCT04524702 |
Source: Clinicaltrials.gov. 1 All-trans retinoic acid.